Jasmine (Drospirenone, Ethinylestradiol)

The combination works by suppressing the hypothalamic‑pituitary‑ovarian axis, which inhibits the mid‑cycle surge of luteinizing hormone and prevents ovulation. Drospirenone also thickens cervical mucus, making it hostile to sperm, while ethinylestradiol induces endometrial changes that reduce the likelihood of implantation.

The dosage regimen for Jasmine is determined by the prescribing clinician. Typically, the product is taken once daily at the same time for a 21‑day active pill sequence followed by a hormone‑free interval, but the exact schedule and pack size are set by the healthcare provider.

Jasmine is contraindicated in pregnancy (Category X) and must be discontinued if pregnancy occurs. Limited data are available for breastfeeding; however, combined oral contraceptives are generally considered compatible with lactation, though clinicians may prefer progestin‑only methods during early postpartum periods.

To place an order, submit an enquiry on the Jasmine product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jasmine contains drospirenone, a progestin with anti‑aldosterone and anti‑androgenic properties, which may offer benefits such as reduced water retention compared with levonorgestrel‑based pills. Efficacy in preventing pregnancy is comparable across approved combined oral contraceptives, while side‑effect profiles can differ based on the progestin component.

Jasmine tablets should be stored at temperatures below 25 °C, in the original blister pack, protected from moisture, heat and direct sunlight. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Jasmine is taken orally, once daily, preferably at the same time each day. The typical regimen consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval during which withdrawal bleeding occurs. Patients should not skip doses and should follow the prescribing clinician’s instructions.

The most serious risks include venous thromboembolism, arterial thrombosis, myocardial infarction, stroke, and severe hypertension. These events are more likely in women who smoke, are over 35 years old, have a history of clotting disorders, or have uncontrolled cardiovascular risk factors. Immediate medical attention is required if symptoms such as chest pain, shortness of breath or sudden severe headache develop.

Jasmine should not be used by women who are pregnant, have known or suspected estrogen‑dependent tumors, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are smokers over the age of 35. It is also contraindicated in individuals with known hypersensitivity to drospirenone, ethinylestradiol or any excipients in the tablet.